Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION-BP
NCT04971720Phase 3Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in hypertension (HTN) (4 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Change in mean nocturnal systolic blood pressure at 28 days. Started Feb 2022; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04971720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971720.